Compliance Rate
Compliance Rate
0%
Compliant submissions
0
Incompliant submissions
0
Total trials
0
My Organizations' Clinical Trials
Showing 2 of 2 entries
View as:
Phase: N/A
Priority: Normal
Start: 01/08/24
End: 12/31/28
Due: 12/31/29
Phase: N/A
Priority: Normal
Start: 05/03/22
End: 12/31/23
Due: 12/31/24
| Title | NCT ID | Organization | User | Status | Start Date | End Date | Reporting Due Date | Last Checked | User Role | Org Created |
|---|---|---|---|---|---|---|---|---|---|---|
| Venetoclax, Daratumumab, and Dexamethasone for Systemic Light-Chain Amyloidosis With Translocation (11;14) (ALTITUDE) | NCT05486481 | Alfred Chung, MD | user2@example.com | None | 2024-01-08 | 2028-12-31 | 2029-12-31 | - | - | 2025-07-14 |
| Pembrolizumab for the Treatment of Relapsed or Refractory Multiple Myeloma After Anti-BCMA CAR-T Therapies | NCT05191472 | Alfred Chung, MD | user2@example.com | None | 2022-05-03 | 2023-12-31 | 2024-12-31 | - | - | 2025-07-14 |